Fennec Pharmaceuticals Announces Public Offering to Fund Debt Reduction and Operations
Key Insights
Fennec Pharmaceuticals announced an underwritten registered public offering of common shares with Piper Sandler & Co. (search) and Craig-Hallum Capital Group LLC (search) serving as joint book-running managers.
The company plans to use net proceeds primarily to repurchase and redeem certain indebtedness, with remaining funds allocated for working capital and general corporate purposes.
Fennec has granted underwriters a 30-day option to purchase up to an additional 15% of common shares sold in the public offering.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) announced on November 13, 2025, that it intends to offer and sell common shares in an underwritten registered public offering. The specialty pharmaceutical company has granted underwriters a 30-day option to purchase up to an additional 15% of the common shares sold in the public offering.
Financial Strategy and Use of Proceeds
Fennec intends to use the net proceeds of the proposed offering to repurchase and redeem certain indebtedness, with any remaining net proceeds allocated for working capital and general corporate purposes. The offering is being conducted pursuant to a registration statement previously filed with and declared effective by the Securities and Exchange Commission.
Piper Sandler & Co. (search) and Craig-Hallum Capital Group LLC (search) are serving as the joint book-running managers for the proposed public offering. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and made available on the SEC's website.
Company Focus and Product Portfolio
Fennec Pharmaceuticals is a specialty pharmaceutical company committed to fighting ototoxicity (search) in cancer (search) patients who receive cisplatin-based chemotherapy. The company focuses on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients.
PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023. The drug also received United Kingdom approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. (search), a leading European specialist pharmaceutical company, to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Market Protection and Patent Coverage
PEDMARK® has received Orphan Drug Exclusivity in the U.S., while PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Fennec holds patents providing protection for PEDMARK® until 2039 in both the U.S. and internationally.
PEDMARQSI® is currently commercially available in the U.K. and Germany, expanding the company's international market presence.
Regulatory Considerations
The common shares in the proposed offering will not be offered or sold, directly or indirectly, in Canada or to any resident of Canada. The company has noted that forward-looking statements are subject to various risks and uncertainties, including regulatory and guideline developments, manufacturing capabilities, clinical results replication, and market penetration challenges.